Skip to main content
SpringerLink
Log in

Adjuvant Therapy in Locally Advanced Prostate Cancer

  • Chapter
  • First Online:
Management of Advanced Prostate Cancer

  • 828 Accesses

Abstract

In the treatment of locally advanced prostate cancer (PCa), there currently exists no established spectrum of treatment options to include adjuvant therapy. Adjuvant radiotherapy (RT) and adjuvant hormonal therapy (HT) could be included as treatment options. In considering therapeutic options for treating HT, both short-term therapy and long-term therapy could be included. Generally, current evidence supports surgical intervention (radical prostatectomy “RP” or “RT”) with adjuvant RT or HT as the optimal curative therapeutic option(s) for treating the cancer. Although high-risk PCa is not the centerpiece topic for this chapter, evidence suggests that the addition of adjuvant HT could serve to produce a more favorable outcome in those cases. In this chapter, the current status of adjuvant therapy (RT and HT) as a treatment option as well as how well adjuvant treatment performs in conjunction with the relative role(s) of RP and/or RT shall be discussed in greater detail, below.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Berglund RK, Jones JS, Ulchaker JC, Fergany A, Gill I, Kaouk J, et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology. 2006;67(6):1253–6.

    Article  PubMed  Google Scholar 

  2. Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol. 2006;176(2):564–8.

    Article  PubMed  Google Scholar 

  3. Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC. Radical prostatectomy for clinical stage T3a disease. Cancer. 2007;109(7):1273–8.

    Article  PubMed  Google Scholar 

  4. Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology. 2007;69(6):1170–5.

    Article  PubMed  Google Scholar 

  5. Masterson TA, Pettus JA, Middleton RG, Stephenson RA. Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: prognostic stratification of pt3b disease by nodal and margin status. Urology. 2005;66(1):152–5.

    Article  PubMed  Google Scholar 

  6. Secin FP, Bianco FJ Jr, Vickers AJ, Reuter V, Wheeler T, Fearn PA, et al. Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy. Cancer. 2006;106(11):2369–75.

    Article  PubMed  Google Scholar 

  7. Boccon-Gibod L, Bertaccini A, Bono AV, Dev Sarmah B, Holtl W, Mottet N, et al. Management of locally advanced prostate cancer: a European consensus. Int J Clin Pract. 2003;57(3):187–94.

    PubMed  CAS  Google Scholar 

  8. Hodgson D, Warde P, Gospodarowicz M. The management of locally advanced prostate cancer. Urol Oncol. 1998;4(1):3–12.

    Article  CAS  PubMed  Google Scholar 

  9. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–37.

    Article  PubMed  Google Scholar 

  10. Porcaro AB, De Luyk N, Corsi P, Sebben M, Tafuri A, Processali T, et al. Clinical factors predicting bilateral lymph node invasion in high-risk prostate cancer. Urol Int. 2017;99:392–9.

    Article  PubMed  Google Scholar 

  11. Gallina A, Chun FK, Briganti A, Shariat SF, Montorsi F, Salonia A, et al. Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. Eur Urol. 2007;52(1):98–105.

    Article  PubMed  Google Scholar 

  12. Joniau S, Hsu CY, Lerut E, Van Baelen A, Haustermans K, Roskams T, et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol. 2007;51(2):388–94. discussion 95-6.

    Article  CAS  PubMed  Google Scholar 

  13. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol. 2007;51(1):121–8. discussion 8-9

    Article  PubMed  Google Scholar 

  14. Hsu CY, Joniau S, Roskams T, Oyen R, Van Poppel H. Comparing results after surgery in patients with clinical unilateral T3a prostate cancer treated with or without neoadjuvant androgen-deprivation therapy. BJU Int. 2007;99(2):311–4.

    Article  PubMed  Google Scholar 

  15. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95(6):751–6.

    Article  PubMed  Google Scholar 

  16. Johnstone PA, Ward KC, Goodman M, Assikis V, Petros JA. Radical prostatectomy for clinical T4 prostate cancer. Cancer. 2006;106(12):2603–9.

    Article  PubMed  Google Scholar 

  17. Wallis CJD, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R, et al. Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(1):21–30.

    Article  PubMed  Google Scholar 

  18. Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol. 2015;33(19):2143–50.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Kitsukawa S, et al. Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution. Int J Clin Oncol. 2014;19(6):1085–91.

    Article  CAS  PubMed  Google Scholar 

  20. Raina R, Agarwal A, Goyal KK, Jackson C, Ulchaker J, Angermeier K, et al. Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. Urology. 2003;62(6):1103–8.

    Article  PubMed  Google Scholar 

  21. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018–27.

    Article  PubMed  Google Scholar 

  22. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296(19):2329–35.

    Article  CAS  PubMed  Google Scholar 

  23. Fahmy O, Khairul-Asri MG, Hadi S, Gakis G, Stenzl A. The role of radical prostatectomy and radiotherapy in treatment of locally advanced prostate cancer: a systematic review and meta-analysis. Urol Int. 2017;99:249–56.

    Article  CAS  PubMed  Google Scholar 

  24. Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017;35(5):183–91.

    Article  CAS  PubMed  Google Scholar 

  25. Gupta D, Salmane C, Slovin S, Steingart RM. Cardiovascular complications of androgen deprivation therapy for prostate cancer. Curr Treat Options Cardiovasc Med. 2017;19(8):61.

    Article  PubMed  Google Scholar 

  26. Keating NL. Type of androgen deprivation therapy and risk of cardiovascular disease. Eur Urol. 2017;72:929–30.

    Article  PubMed  Google Scholar 

  27. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–73.

    Article  CAS  PubMed  Google Scholar 

  28. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956–62.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66(2):243–50.

    Article  PubMed  Google Scholar 

  30. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol. 2013;190(2):441–9.

    Article  PubMed  Google Scholar 

  31. Ku JY, Lee CH, Ha HK. Long-term oncologic outcomes of postoperative adjuvant versus salvage radiotherapy in prostate cancer: systemic review and meta-analysis of 5-year and 10-year follow-up data. Korean J Urol. 2015;56(11):735–41.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai KH, et al. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol. 2012;13(12):1260–70.

    Article  CAS  PubMed  Google Scholar 

  33. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61(5):1285–90.

    Article  CAS  PubMed  Google Scholar 

  34. Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26(4):585–91.

    Article  PubMed  Google Scholar 

  35. Zhou ZR, Zhu XD, Xia J, Zou ZY, Qu S, Zeng XT, et al. Short-term versus long-term hormone therapy plus radiotherapy or prostatectomy for prostate cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2013;139(5):783–96.

    Article  CAS  PubMed  Google Scholar 

  36. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol. 2001;166(2):500–6. discussion 6-7.

    Article  CAS  PubMed  Google Scholar 

  37. Pu XY, Wang XH, Wu YL, Wang HP. Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy. J Cancer Res Clin Oncol. 2007;133(8):555–62.

    Article  CAS  PubMed  Google Scholar 

  38. Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21(10):1904–11.

    Article  PubMed  Google Scholar 

  39. Montgomery B, Lavori P, Garzotto M, Lee K, Brophy M, Thaneemit-Chen S, et al. Veterans Affairs Cooperative Studies Program study 553: chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology. 2008;72(3):474–80.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, South Korea

    Jae Heon Kim

Authors
  1. Jae Heon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Asan Medical Center, Seoul, Soul-t´ukpyolsi, Korea (Republic of)

    Choung Soo Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kim, J.H. (2018). Adjuvant Therapy in Locally Advanced Prostate Cancer. In: Kim, C. (eds) Management of Advanced Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-6943-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-6943-7_6

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-6942-0

  • Online ISBN: 978-981-10-6943-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation